01 / THE ARGUMENT
Change the unit of business
The most consequential obesity-care contract may be the one that begins after the initial prescription. My thesis is that treatment continuity should become an explicit product with its own accountable owner, budget and outcome measures. A pharmacy claim documents a transaction. It does not establish that the patient can obtain the next prescription, tolerate treatment, navigate a coverage change or receive an appropriate alternative when circumstances change.
This changes the commercial question from how many people can start treatment to how many can sustain an acceptable clinical pathway. Continuity does not mean keeping every person on the same medicine indefinitely. It means preventing avoidable gaps while supporting clinician-directed adjustment, switching or cessation. A business that confuses persistence with compulsory continuation will distort both patient choice and its performance measures.
02 / THE ARGUMENT
What withdrawal evidence establishes
West and colleagues' 2026 BMJ systematic review included 37 studies and 9,341 participants, with average post-treatment follow-up of 32 weeks. Across weight-management medications, average regain after cessation was 0.4 kg per month (95% CI 0.3–0.5). The evidence mixes drugs and study designs; estimates extrapolating return to baseline are model projections, not years of direct observation for every participant. It supports concern about short treatment episodes, but does not establish that every person needs lifelong treatment or that one support service prevents regain. [1]
The operating inference is narrower and more useful: a benefit design should disclose and fund what happens when the initial phase ends. An authorization expiry is an administrative event, not a clinical maintenance strategy. Managers should distinguish clinically appropriate cessation, patient preference, adverse effects and access failure; pooling them into one discontinuation rate conceals which problems the organization can actually solve.
03 / THE ARGUMENT
Maintenance can be a different treatment phase
The 2026 ATTAIN-MAINTAIN trial randomized 376 previous SURMOUNT-5 participants to oral orforglipron or placebo after injectable treatment. Among participants reaching a weight plateau, model-estimated retention of prior weight reduction at 52 weeks was 74.7% versus 49.2% following tirzepatide and 79.3% versus 37.6% following semaglutide. Placebo participants could receive rescue orforglipron from week 24; these modeled estimates incorporate the trial’s handling of rescue treatment and are not simple observed outcomes under uninterrupted placebo. The trial lacked a continued-injectable comparator, lasted one year and enrolled selected previous trial participants. Its findings do not demonstrate equivalence to continued injections, lower total cost or improved cardiovascular outcomes. [2]
My strategic interpretation is that maintenance deserves a separate service design. A clinically supervised transition can require different dispensing, education and follow-up than initiation. Purchasing teams should evaluate a pathway's capacity to manage those transitions, rather than assume that changing administration route automatically removes adherence barriers. The value proposition is optionality supported by evidence, with exceptions retained for people whose clinical circumstances do not match a proposed pathway.
04 / THE ARGUMENT
Separate lifetime value from this year's cash requirement
Hwang and colleagues' 2025 JAMA Health Forum analysis used a US lifetime microsimulation, informed by 4,823 survey participants, to compare obesity medicines plus lifestyle modification with lifestyle modification alone. Under its price and clinical assumptions, estimated incremental cost-effectiveness ratios were $197,023 per quality-adjusted life-year for tirzepatide and $467,676 for semaglutide. These are modeled results using historical inputs, not current transaction prices or observed savings. Their ranking should not be imported unchanged into a 2026 procurement decision. [3]
For an operator, annual budget impact can instead be written as B = N × (D + S + M) + F − A. N is treated member-years; D is net medicine cost; S is support cost; M is monitoring and adverse-event cost; F is implementation cost; and A is medical expenditure actually avoided within the budget horizon. Every input needs a local source. Longer persistence may increase D before any offset appears. A cost-effective service can therefore still require additional annual funding.
05 / THE ARGUMENT
Make the payer–pharmacy interface accountable
Consider a health plan contracting with a pharmacy and a clinician network for an illustrative, twelve-month service pilot. The plan's clinical operations director owns the pathway, with the pharmacy lead responsible for access exceptions and the prescribing service responsible for clinical decisions. Renewal work begins before supply ends. Patients receive a named contact, and unresolved authorization, affordability or tolerability problems enter a shared queue with an escalation owner.
The counterfactual is the same coverage and formulary with the existing renewal workflow. A phased rollout across comparable practices, preferably randomized where feasible, can test whether the service improves continuity rather than merely attracting more engaged patients. Finance approves a fixed implementation ceiling and a per-enrolled-member service fee. Drug expenditure remains visible in the total budget: hiding it outside the pilot would make an apparently successful service impossible to assess commercially.
06 / THE ARGUMENT
Define failure before negotiating success fees
A continuation bonus alone would reward the wrong behavior. The proposed scorecard pairs avoidable access gaps with patient-reported burden, documented clinical review, treatment changes, adverse-event escalation, maintenance of agreed clinical goals and total spending. Results should be stratified by baseline risk and access barriers so that the service cannot improve its average simply by excluding difficult-to-serve members. Missing outcomes must stay visible in the denominator.
The thesis would weaken if comparable patients maintained the same outcomes and experienced no additional access failures under a less intensive service. It would also fail commercially if incremental support expenditure consistently exceeded the purchaser's pre-agreed willingness to pay for the observed improvement. Short follow-up cannot establish lifetime savings. Conversely, an absence of twelve-month medical savings does not by itself refute a service whose explicitly funded purpose is improved health and continuity.
07 / THE ARGUMENT
The executive decision
Authorize a bounded continuity pilot before paying for broad prescription growth. Require transparent net prices, a clinical transition policy, an accessible exceptions process and an evaluation against ordinary care. Negotiate operational commitments that the partner can control, while retaining clinical decisions with qualified professionals and meaningful choice with patients.
The durable business opportunity is the ability to carry people through changes in treatment and coverage without repeatedly rebuilding the care relationship. Whether that capability earns an economic return remains a local, testable question. It should be purchased as a service with evidence obligations, not assumed to emerge from prescription fulfillment.
FROM THESIS TO ALLOCATION
A bounded business case
Proposed operating design and evaluation criteria. These are the author’s recommendations, not outcomes established by the cited studies.
- Decision
- Fund a twelve-month, capped pilot of renewal and transition support under unchanged clinical eligibility criteria.
- Accountable owner
- Health-plan clinical operations director, jointly accountable with pharmacy operations and the prescribing network.
Delivery workflow
- Identify upcoming renewal or supply interruptions with patient consent and current dispensing information.
- Route administrative barriers to pharmacy operations and clinical questions to the prescribing team.
- Document the patient's preferred, clinician-approved continuation or transition plan.
- Compare participating practices with an equivalent usual-workflow cohort and report all enrolled members.
Economic logic
Evaluate incremental support and medicine spending against measured outcomes; estimate avoided medical expenditure only within an explicit horizon and counterfactual. The B equation is a proposed accounting framework, not a published cost-effectiveness result.
Success measures
- Avoidable interruption days
- Patient burden and access by subgroup
- Documented clinical review of transitions
- Maintained clinical goals
- Total cost per enrolled member-year
Stop or redesign when
Pause expansion if access or outcomes do not improve against the counterfactual, safety escalation fails, or incremental cost exceeds the prospectively approved service budget.
THE EVIDENCE LEDGER
What each study can support
Study findings and limitations are kept separate from the operating proposals above.
| Study | Design | Verified finding | Boundary |
|---|---|---|---|
| [1] The BMJ | Systematic review and meta-analysis of randomized, nonrandomized and observational studies. | 37 studies; 9,341 participants; mean regain 0.4 kg/month (95% CI 0.3–0.5) across medications after cessation. | Heterogeneous interventions and follow-up; longer-term return-to-baseline estimates were extrapolated. |
| [2] Nature Medicine | Double-blind, randomized, placebo-controlled phase 3b trial in 376 previous SURMOUNT-5 participants. | At week 52, plateau-subgroup modeled retention of prior weight loss favored orforglipron in both previous-injectable cohorts. | No continued-injectable control; one-year follow-up; selected trial completers and rescue-treatment handling constrain interpretation. |
| [3] JAMA Health Forum | Lifetime US health-economic microsimulation using NHANES 2017–2020 inputs, performed in 2024. | Modeled ICERs: tirzepatide $197,023/QALY; semaglutide $467,676/QALY, under the analysis's historical assumptions. | Lifetime projections, model structure and historical prices cannot establish current purchaser savings. |
FOLLOW THE SOURCE
Sources and editorial method
Original strategic interpretation of selected peer-reviewed evidence searched through 27 September 2026; not an exhaustive latest-paper ranking, a journal publication, patient-specific advice or investment advice. Azis R. Dabas is the editorial author, not an author of the cited studies. Current drug prices, coverage and local prescribing requirements require separate verification.
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
Sam West, Jadine Scragg, Paul Aveyard, et al.. The BMJ. .
DOI: 10.1136/bmj-2025-085304 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 140. Counts are a dated index snapshot, not an assessment of study quality.
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Louis J. Aronne, Deborah B. Horn, Carel W. le Roux, et al.. Nature Medicine. .
DOI: 10.1038/s41591-026-04386-7 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 16. Counts are a dated index snapshot, not an assessment of study quality.
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Jennifer H. Hwang, Neda Laiteerapong, Elbert S. Huang, David D. Kim. JAMA Health Forum. .
DOI: 10.1001/jamahealthforum.2024.5586 · Primary verification record · Consensus paper record
Consensus citation count at retrieval: 74. Counts are a dated index snapshot, not an assessment of study quality.
Affiliations and study authorship belong to the cited researchers. No institutional affiliation or endorsement of this editorial analysis is implied. Publication dates use the verified source precision; a month-only date identifies an issue month.